BRIGHT MINDS BIOSCIENCES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.29 CAD | -12.24% |
|
-21.82% | -39.15% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Bright Minds Biosciences Inc. is a biotechnology company. The Company is focused on developing transformative treatments for neuropsychiatric disorders, epilepsy, and pain. It has a portfolio of next generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as treatment resistant epilepsy, treatment resistant depression, post-traumatic stress disorder (PTSD), and pain. Its pipeline includes BMB-101, BMB-202, and BMB-xxx. BMB-101 is for the treatment of Dravet syndrome and other neurological and neuro-psychiatric disorders. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling while avoiding off-target effects.
Calendar
2024-05-26
- Q2 2024 Earnings Release (Projected)
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -39.15% | 4.22M | |
| +0.67% | 42.4B | |
| +44.30% | 40.04B | |
| -6.20% | 28.31B | |
| +6.55% | 24.94B | |
| -21.66% | 18.96B | |
| +29.96% | 12.3B | |
| -1.57% | 11.95B | |
| +16.03% | 11.32B | |
| -4.80% | 11.55B |
- Stock Market
- Equities
- DRUG Stock
- News Bright Minds Biosciences Inc.
- Bright Minds Biosciences Brief: Announced "Positive" Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101
